LynxDx

Our mission is to develop superior genomic tests where there is a clear patient need. We are and will continue to be a premier employer, encouraging individual and team contributions, honesty, and accountability. Our goal is to provide a solution with zero surprises for all involved. Lynx Dx provides best-in-class diagnostic testing services to help people live healthy and productive lives. Our Leadership Team deeply cares about improving risk assessment for prostate cancer and offers decades of diverse experience to support the mission. The resulting screening test MyProstateScore (MPS) has provided patients with individualized, non-invasive risk assessments for prostate cancer by measuring urine levels of two unique cancer genes, T2:ERG and PCA3. Our drive-thru testing network became one of the nation’s leading COVID-19 testing lab operations. They discovered 18 unique genes—including the T2:ERG transcripts—that, when analyzed together, offer a clear and highly individualized prediction of a patient’s risk of having clinically significant prostate cancer.